S&P 500   5,023.88 (-0.55%)
DOW   37,742.96 (-0.15%)
QQQ   426.26 (-1.12%)
AAPL   168.20 (-0.70%)
MSFT   411.91 (-0.64%)
META   495.05 (-0.94%)
GOOGL   155.69 (+0.84%)
AMZN   181.23 (-1.14%)
TSLA   156.65 (-0.29%)
NVDA   845.45 (-3.28%)
AMD   155.00 (-5.18%)
NIO   3.94 (+3.41%)
BABA   68.96 (-0.93%)
T   16.14 (+0.31%)
F   12.04 (-0.41%)
MU   116.64 (-4.21%)
GE   155.47 (-0.82%)
CGC   6.41 (-4.33%)
DIS   113.22 (-0.58%)
AMC   2.98 (+9.56%)
PFE   25.43 (-1.01%)
PYPL   63.29 (-0.22%)
XOM   118.51 (-0.15%)
S&P 500   5,023.88 (-0.55%)
DOW   37,742.96 (-0.15%)
QQQ   426.26 (-1.12%)
AAPL   168.20 (-0.70%)
MSFT   411.91 (-0.64%)
META   495.05 (-0.94%)
GOOGL   155.69 (+0.84%)
AMZN   181.23 (-1.14%)
TSLA   156.65 (-0.29%)
NVDA   845.45 (-3.28%)
AMD   155.00 (-5.18%)
NIO   3.94 (+3.41%)
BABA   68.96 (-0.93%)
T   16.14 (+0.31%)
F   12.04 (-0.41%)
MU   116.64 (-4.21%)
GE   155.47 (-0.82%)
CGC   6.41 (-4.33%)
DIS   113.22 (-0.58%)
AMC   2.98 (+9.56%)
PFE   25.43 (-1.01%)
PYPL   63.29 (-0.22%)
XOM   118.51 (-0.15%)
S&P 500   5,023.88 (-0.55%)
DOW   37,742.96 (-0.15%)
QQQ   426.26 (-1.12%)
AAPL   168.20 (-0.70%)
MSFT   411.91 (-0.64%)
META   495.05 (-0.94%)
GOOGL   155.69 (+0.84%)
AMZN   181.23 (-1.14%)
TSLA   156.65 (-0.29%)
NVDA   845.45 (-3.28%)
AMD   155.00 (-5.18%)
NIO   3.94 (+3.41%)
BABA   68.96 (-0.93%)
T   16.14 (+0.31%)
F   12.04 (-0.41%)
MU   116.64 (-4.21%)
GE   155.47 (-0.82%)
CGC   6.41 (-4.33%)
DIS   113.22 (-0.58%)
AMC   2.98 (+9.56%)
PFE   25.43 (-1.01%)
PYPL   63.29 (-0.22%)
XOM   118.51 (-0.15%)
S&P 500   5,023.88 (-0.55%)
DOW   37,742.96 (-0.15%)
QQQ   426.26 (-1.12%)
AAPL   168.20 (-0.70%)
MSFT   411.91 (-0.64%)
META   495.05 (-0.94%)
GOOGL   155.69 (+0.84%)
AMZN   181.23 (-1.14%)
TSLA   156.65 (-0.29%)
NVDA   845.45 (-3.28%)
AMD   155.00 (-5.18%)
NIO   3.94 (+3.41%)
BABA   68.96 (-0.93%)
T   16.14 (+0.31%)
F   12.04 (-0.41%)
MU   116.64 (-4.21%)
GE   155.47 (-0.82%)
CGC   6.41 (-4.33%)
DIS   113.22 (-0.58%)
AMC   2.98 (+9.56%)
PFE   25.43 (-1.01%)
PYPL   63.29 (-0.22%)
XOM   118.51 (-0.15%)
NASDAQ:CLBT

Cellebrite DI (CLBT) Stock Price, News & Analysis

$10.43
-0.07 (-0.67%)
(As of 03:27 PM ET)
Today's Range
$10.39
$10.58
50-Day Range
$9.25
$12.29
52-Week Range
$5.22
$12.50
Volume
283,862 shs
Average Volume
960,619 shs
Market Capitalization
$2.14 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.30

Cellebrite DI MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
17.9% Upside
$12.30 Price Target
Short Interest
Healthy
4.47% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.77mentions of Cellebrite DI in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
28.13%
From $0.32 to $0.41 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.57 out of 5 stars

Business Services Sector

176th out of 310 stocks

Prepackaged Software Industry

122nd out of 197 stocks

CLBT stock logo

About Cellebrite DI Stock (NASDAQ:CLBT)

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft. It provides Inseyets, a digital forensics software that collects and reviews digital evidence from various digital sources when conducting legally sanctioned investigations. The company's digital forensics software also offers data extraction, decoding capabilities, workflows, and automation capabilities. In addition, it provides Cellebrite Pathfinder, which reduces the time spent manually reviewing digital evidence by automating data analysis and visualization; Smart Search, an open source intelligence tool that automates the collection and review of publicly available online data; and Guardian, a case and evidence management solution. Further, the company offers digital forensic software for enterprises and service providers, including Inseyets for Enterprise, Endpoint Inspector, and Mobile Now; and professional services, such as training and certification services, and other services. It serves federal and state and local agencies. The company was incorporated in 1999 and is headquartered in Petah Tikva, Israel.

CLBT Stock Price History

CLBT Stock News Headlines

The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Cellebrite Files its 2023 Annual Report on Form 20-F
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Cellebrite Files its 2023 Annual Report on Form 20-F
UPDATE – Cellebrite Announces 2024 Investor Day
Cellebrite Announces 2024 Investor Day
William Blair Keeps Their Hold Rating on Cellebrite DI (CLBT)
Cellebrite (CLBT) Benefitting from Increased Data Volume
See More Headlines
Receive CLBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellebrite DI and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Today
4/17/2024
Next Earnings (Confirmed)
5/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Prepackaged software
Sub-Industry
N/A
Current Symbol
NASDAQ:CLBT
Employees
1,008
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.30
High Stock Price Target
$16.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+17.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-81,100,000.00
Pretax Margin
-23.24%

Debt

Sales & Book Value

Annual Sales
$325.11 million
Cash Flow
$0.27 per share
Book Value
$0.18 per share

Miscellaneous

Free Float
193,595,000
Market Cap
$2.16 billion
Optionable
Optionable
Beta
1.54
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Yossi Carmil (Age 56)
    Founder, CEO & Director
    Comp: $1.14M
  • Ms. Dana Gerner (Age 57)
    Chief Financial Officer
    Comp: $649k
  • Mr. Ronnen Armon (Age 61)
    Chief Products & Technologies Officer
    Comp: $516k
  • Ms. Lisa Cole (Age 49)
    Chief Marketing Officer
    Comp: $499k
  • Mr. Leeor Ben-Peretz (Age 48)
    Chief Strategy Officer
    Comp: $470k
  • Mr. Thomas E. Hogan (Age 65)
    Executive Chairman
  • Mr. Arnon Zilberman
    Executive Vice President of Information Systems & Operations
  • Andrew Kramer
    Vice President of Investor Relations
  • Ms. Ayala Berler Shapira (Age 53)
    General Counsel & Chief Compliance Officer
  • Ms. Zohar Tadmor-Eilat (Age 53)
    Chief People Officer

CLBT Stock Analysis - Frequently Asked Questions

Should I buy or sell Cellebrite DI stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cellebrite DI in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CLBT shares.
View CLBT analyst ratings
or view top-rated stocks.

What is Cellebrite DI's stock price target for 2024?

5 equities research analysts have issued 12-month target prices for Cellebrite DI's stock. Their CLBT share price targets range from $9.00 to $16.00. On average, they predict the company's share price to reach $12.30 in the next twelve months. This suggests a possible upside of 17.9% from the stock's current price.
View analysts price targets for CLBT
or view top-rated stocks among Wall Street analysts.

How have CLBT shares performed in 2024?

Cellebrite DI's stock was trading at $8.66 at the beginning of the year. Since then, CLBT stock has increased by 20.4% and is now trading at $10.43.
View the best growth stocks for 2024 here
.

Are investors shorting Cellebrite DI?

Cellebrite DI saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 2,480,000 shares, a drop of 5.3% from the March 15th total of 2,620,000 shares. Based on an average daily volume of 998,300 shares, the short-interest ratio is currently 2.5 days. Currently, 4.5% of the company's stock are short sold.
View Cellebrite DI's Short Interest
.

When is Cellebrite DI's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 23rd 2024.
View our CLBT earnings forecast
.

How can I listen to Cellebrite DI's earnings call?

Cellebrite DI will be holding an earnings conference call on Thursday, May 23rd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Cellebrite DI's earnings last quarter?

Cellebrite DI Ltd. (NASDAQ:CLBT) issued its earnings results on Thursday, February, 15th. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.02. The company earned $93.01 million during the quarter, compared to analysts' expectations of $85.43 million. Cellebrite DI had a negative net margin of 24.94% and a positive trailing twelve-month return on equity of 173.14%.

What ETFs hold Cellebrite DI's stock?

ETFs with the largest weight of Cellebrite DI (NASDAQ:CLBT) stock in their portfolio include ARK Israel Innovative Technology ETF (IZRL).Amplify BlueStar Israel Technology ETF (ITEQ).

What guidance has Cellebrite DI issued on next quarter's earnings?

Cellebrite DI issued an update on its first quarter 2024 earnings guidance on Friday, February, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $83.0 million-$88.0 million, compared to the consensus revenue estimate of $84.3 million.

Who are Cellebrite DI's major shareholders?

Cellebrite DI's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Counterpoint Mutual Funds LLC (0.03%) and Hennessy Advisors Inc. (0.01%).

How do I buy shares of Cellebrite DI?

Shares of CLBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CLBT) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners